|Bid||97.50 x 900|
|Ask||98.40 x 1300|
|Day's Range||95.45 - 98.79|
|52 Week Range||78.06 - 181.83|
|Beta (5Y Monthly)||2.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 24, 2021 - Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||126.95|
Pfizer sees coronavirus vaccines as a "durable" business, one executive said recently. But don't expect Pfizer stock to be hung up on Covid-19 in 2021. The company sees plenty of catalysts.
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on Exondys 51 for near-term growth is a concern.
LOS ANGELES, CA / ACCESSWIRE / January 15, 2021 /The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT) for violations of the securities laws.